|Clinical Trial Title
|Open to Enrollment
|Doctors & Locations
This is a 52-week, Phase 3, open-label, single-arm, multicenter study to assess the local and systemic safety and tolerability, as well as efficacy, of ABBV-951 administered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up to 52 weeks.
ABBV-951 enables continuous, subcutaneous, and individualized delivery of carbidopa/levodopa (CD/LD), covering the wide range of levodopa doses required to adequately control motor symptoms in patients with advanced PD. Therefore, this novel treatment may provide an alternative therapy to many patients whose motor complications are inadequately controlled by their current treatment.
The investigational product consists of study drug (solution for infusion) and study devices.
Subjects will have 11 study visits in the treatment period over 52 weeks
Ages Eligible for Study: 30 years and older
Sexes Eligible for Study: All
|Richard Rosenbaum, MD